See Covering the Cover synopsis on 271. See editorial on page 300.

Although considered as a new drug of abuse, gamma-hydroxybutyrate, or GHB, has been used clinically since the 1960s as an intravenous anesthetic. It was also investigated for treatment of insomnia, of alcohol and opiate withdrawal syndrome, and in cerebrovascular disorders. GHB is a substance naturally present within mammalian species. Properties of neurotransmitter or neuromodulator are generally given to this substance (1,2). Doses of 10 mg/kg cause amnesia; 20 to 30 mg/kg cause sleep; and doses of 50 mg/kg or higher produce anesthesia. Illicit use of GHB typically involves doses of 35 mg/kg (3). People exposed to GHB involve: bodybuilders who believe that the drug stimulates the release of growth hormone, even if this activity is still under debate (4); ravers or club attendees for its intoxicating effects, such as euphoria, reduced inhibitions, sedation, and muscle relaxation that can benefit after ecstasy abuse (5); drivers as a result of recreational abuse (6); and victims of drug-facilitated sexual assault (7). The purported enhancement of sexuality, coupled with a possible abrupt coma-inducing effect, ease of administration in spiked drinks, and potential amnesia have resulted in the use of GHB as an assault-related drug. GHB is also attractive to rapists as it is readily available (Internet, on the street, in dance clubs or fitness centers).

No abstract